News GSK builds neuro, cancer pipeline with trio of deals GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.
News FDA clears AZ's Imfinzi for aggressive lung cancer AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
News Merus grabs first-in-class US approval for NRG1 cancer drug Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer
News Genmab expands its pipeline with $630m Scancell deal Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
News Gilead looks beyond Trodelvy with Tubulis alliance Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
News Ipsen doubles up in TCEs for cancer, adding Biomunex drug Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.
News Lilly invests another $3bn in its manufacturing network Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.